期刊文献+

老年骨质疏松性骨折患者血清PTX3、Sema4d对术后骨折再发的预测价值

Predictive value of serum PTX3 and Sema4d for postoperative fracture recurrence in elderly patients with osteoporotic fracture
下载PDF
导出
摘要 目的探讨老年骨质疏松性骨折(OPF)患者血清中正五聚蛋白3(PTX3)和信号素4D(Sema4d)对术后骨折再发的预测价值。方法选取2022年1月至2023年1月于该院就诊的168例老年OPF患者,根据术后骨折是否再发将患者分成非再发组(116例)和再发组(52例)。采用酶联免疫吸附试验检测血清中的PTX3、Sema4d水平,多因素Logistic回归分析骨折再发的影响因素,Pearson相关分析PTX3水平与Sema4d水平的相关性,受试者工作特征(ROC)曲线分析PTX3、Sema4d水平对术后骨折再发的预测价值,Z检验比较曲线下面积(AUC)。结果再发组与非再发组营养供给不足、穿刺部位、骨密度T值、骨折程度及血清中PTX3、Sema4d水平比较,差异有统计学意义(P<0.05);骨密度T值是术后骨折再发的独立保护因素,骨折程度及血清中PTX3、Sema4d水平是术后骨折再发的独立危险因素(P<0.05);再发组患者血清中PTX3水平与Sema4d呈正相关(r=0.415,P<0.001);PTX3、Sema4d二者联合诊断术后骨折再发的AUC为0.910(95%CI 0.857~0.949),优于血清PTX3、Sema4d单独诊断(Z_(二者联合-PTX3)=3.129、Z_(二者联合-Sema4d)=3.123,均P=0.002)。结论老年OPF术后骨折再发患者血清中PTX3、Sema4d水平升高,PTX3、Sema4d联合诊断老年OPF患者术后骨折再发具有较高价值,可作为早期诊断指标。 Objective To investigate the predictive value of pentraxin 3(PTX3)and semaphorin 4D(Sema4d)in serum for postoperative fracture recurrence in elderly patients with osteoporotic fracture(OPF).Methods A total of 168 elderly patients with OPF who were treated in this hospital from January 2022 to January 2023 were selected.According to the occurrence of postoperative fracture recurrence,the patients were divided into non-recurrence group(116 cases)and recurrence group(52 cases).The levels of PTX3 and Sema4d in serum were detected by enzyme-linked immunosorbent assay.The influencing factors of fracture recurrence were analyzed by multivariate Logistic regression,and the correlation between PTX3 level and Sema4d was analyzed by Pearson correlation.The receiver operating characteristic(ROC)curve was used to analyze the predictive value of PTX3 and Sema4d levels for postoperative fracture recurrence,and Z test was used to compare the area under the curve(AUC).Results There were significant differences in nutritional deficiency,puncture site,bone mineral density T value,fracture degree and serum PTX3,Sema4d levels between recurrence group and non-recurrence group(P<0.05).Bone mineral density T value was an independent protective factor for postoperative fracture recurrence,and fracture degree,serum PTX3,Sema4d levels were independent risk factors for postoperative fracture recurrence(P<0.05).There was a positive correlation between serum PTX3 and Sema4d in recurrence group(r=0.415,P<0.001).The AUC of the combination of PTX3 and Sema4d in the diagnosis of postoperative fracture recurrence was 0.910(95%CI 0.857—0.949),which was better than that of serum PTX3 and Sema4d alone(Z_(combination-PTX3)=3.129,Z_(combination-Sema4D)=3.123,both P=0.002).Conclusion The serum levels of PTX3 and Sema4d are increased in elderly OPF patients with postoperative fracture recurrence.The combination of PTX3 and Sema4d has a high value in the diagnosis of postoperative fracture recurrence in elderly OPF patients,and can be used as an early diagnostic index.
作者 顾伏龙 姜江 沈水杰 王盛 GU Fulong;JIANG Jiang;SHEN Shuijie;WANG Sheng(Department of Orthopedics,Nantong Hospital of Traditional Chinese Medicine,Nantong,Jiangsu 226001,China;Department of Science and Education,Nantong Hospital of Traditional Chinese Medicine,Nantong,Jiangsu 226001,China)
出处 《国际检验医学杂志》 CAS 2024年第11期1343-1347,共5页 International Journal of Laboratory Medicine
基金 南通市科技计划项目(MS32017015)。
关键词 骨质疏松性骨折 正五聚蛋白3 信号素4D 骨折再发 osteoporotic fracture pentraxin 3 semaphorin 4D fractures recurrence
  • 相关文献

参考文献5

二级参考文献55

  • 1Wang G,Yang H,Chen K.Osteoporotic vertebral compression fractures with an intravertebral cleft treated by percutaneous balloon kyphoplasty.J Bone Joint Surg Br,2010,92(11):1553-1557.
  • 2Mao H,Zou J,Geng D,et al.Osteoporotic vertebral fractures without compression:key factors of diagnosis and initial outcome of treatment with cement augmentation.Neuroradiology,2012,54(10):1137-1143.
  • 3Parker M,Johansen A.Hip fracture.BMJ,2006,333(7557):27-30.
  • 4L?nnroos E,Kautiainen H,Karppi P,et al.Incidence of second hip fractures.A population-based study.Osteoporos Int,2007,18(9):1279-1285.
  • 5Black DM,Delmas PD,Eastell R,et al.Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.N Engl J Med,2007,356(18):1809-1822.
  • 6Black DM,Reid IR,Boonen S,et al.The effect of 3 versus6 years of zoledronic acid treatment of osteoporosis:a randomized extension to the HORIZON-Pivotal Fracture Trial(PFT).J Bone Miner Res,2012,27(2):243-254.
  • 7Black DM,Reid IR,Cauley JA,et al.The effect of 6 versus9 years of zoledronic acid treatment in osteoporosis:a randomized second extension to the HORIZON-Pivotal Fracture Trial(PFT).J Bone Miner Res,2015,30(5):934-944.
  • 8Lyles KW,Colón-Emeric CS,Magaziner JS,et al.Zoledronic acid and clinical fractures and mortality after hip fracture.N Engl J Med,2007,357(18):1799-1809.
  • 9Black DM,Schwartz AV,Ensrud KE,et al.Effects of continuing or stopping alendronate after 5 years of treatment:the Fracture Intervention Trial Long-term Extension(FLEX):a randomized trial.JAMA,2006,296(24):2927-2938.
  • 10Bone HG,Hosking D,Devogelaer JP,et al.Ten years'experience with alendronate for osteoporosis in postmenopausal women.N Engl J Med,2004,350(12):1189-1199.

共引文献383

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部